Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 30:8:11.
doi: 10.21037/aob-21-87. Epub 2022 Apr 1.

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

Lucy Zheng  1 , X Long Zheng  1
Affiliations

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

Lucy Zheng et al. Ann Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://aob.amegroups.com/article/view/10.21037/aob-21-87/coif). XLZ serves as an unpaid editorial board member of Annals of Blood from March 2022 to February 2024. XLZ served as a speaker for Alexion and Sanofi, which terminated since last year. He is serving as a consultant for several companies including Alexion, Sanofi, Takeda, and Biomedica. He is also the co-founder of Clotsolution. He received honorarium from several universities and professional conferences as a keynote speaker. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Schematic diagram demonstrates the process for the diagnosis and management of iTTP. When a patient presents with severe thrombocytopenia with platelet count <30×109/L, creatine <2.26 mg/dL in the presence of hemolysis and schistocytes, but no history of malignancy and/or hematopoietic progenitor cell transplantation or known drugs that causes TMA, the likelihood of iTTP is very high (based on French Score). This patient will be benefited from ordering an ADAMTS13 test, immediate TPE and corticosteroids, and early caplacizumab. Otherwise, if the clinical probability of iTTP is low to intermediate, ADAMTS13 test should be ordered prior to TPE and corticosteroid, but no caplacizumab. Use ADAMTS13 activity result to guide further therapies as shown in the bottom of the diagram. This figure is adapted from Zheng et al. (15). *, in most initial iTTP cases, plasma ADAMTS13 activity is less than 5 U/dL (or 5% of normal) or undetectable. Normal ADATMS13 activity is 50–150 U/dL. Those with a relapsed episode may have higher ADAMTS13 activity. TMA, thrombotic microangiopathy; iTTP, immune thrombotic thrombocytopenic purpura. TPE, therapeutic plasma exchange.
See this image and copyright information in PMC

References

    1. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393–7. - PubMed
    1. Staley EM, Cao W, Pham HP, et al. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. Haematologica 2019;104:166–75. - PMC - PubMed
    1. Goel R, King KE, Takemoto CM, et al. Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. Transfusion 2016;56:1451–8. - PMC - PubMed
    1. Balasubramaniyam N, Kolte D, Palaniswamy C, et al. Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura. Am J Med 2013;126:1016.e1–7. - PubMed
    1. Sui J, Lu R, Halkidis K, et al. Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura. J Thromb Haemost 2021;19:370–9. - PMC - PubMed

LinkOut - more resources